Citations

Showing 10 of 108152 citations.

Breast-Gynaecological & Immuno-Oncology International Cancer Conference (BGICC) Consensus and Recommendations for the Management of Triple-Negative Breast Cancer
Elghazaly, Hesham , Azim, Hamdy A., Aapro, Matti , Perez, Edith A. , Anderson, Benjamin O. , Conte, PierFranco , Saghir, Nagi S. El , Yip, Cheng Har , Ghosn, Marwan , Poortmans, Philip , Shehata, Mohamed , Giuliano, Armando E. , Guarneri, Valentina , Aziz, Hany Abdel, Sabry, Mohamed , Balch, Charles M. , Orecchia, Roberto , El‐Zawahry, Heba M., Al‐Sukhun, Sana , Abdelkarim, Khaled , Kandil, Alaa , Al‐Foheidi, Meteb , El‐Shinawi, Mohamed , El-Mahdy, Manal Mohamed, Abulkhair, Omalkhair , Yang, Wentao , Aref, Adel T. , Bakkach, Joaira , Eldin, Nermean Bahie, Elghazawy, Hagar , Conte, Pierfranco , El Saghir, Nagi S , Poortmans, Philip , Al-Sukhun, Sana , Kandil, Alaa , El-Shinawi, Mohamed , Abulkhair, Omalkhair , Elghazawy, Hagar I , Rugo, Hope S. , Swain, Sandra M. , Arun, Banu , Penault-Llorca, Frederique Madeleine , Leung, Jessica W. T. , Gligorov, Joseph , Gulluoglu, Bahadir Mahmut , Фролова, Мона Александровна , Палтуев, Руслан Маликович

Mayo Clinic

Cancers | May 9, 2021 | Volume: 13 | Issue: 9 | Pages: 2262

10.3390/cancers13092262 | PMID 34066769 Get It

Background: The management of patients with triple-negative breast cancer (TNBC) is challenging with several controversies and unmet needs. During the 12th Breast-Gynaecological & Immuno-oncology International Cancer Conference (BGICC) Egypt, 2020, a panel of 35 breast cancer experts from 13 countries voted on consensus guidelines for the clinical management of TNBC. The consensus was subsequently updated based on the most recent data evolved lately. Methods: A consensus conference approach adapted from the American Society of Clinical Oncology (ASCO) was utilized. The panellists voted anonymously on each question, and a consensus was achieved when ≥75% of voters selected an answer. The final consensus was later circulated to the panellists for critical revision of important intellectual content. Results and conclusion: These recommendations represent the available clinical evidence and expert opinion when evidence is scarce. The percentage of the consensus votes, levels of evidence and grades of recommendation are presented for each statement. The consensus covered all the aspects of TNBC management starting from defining TNBC to the management of metastatic disease and highlighted the rapidly evolving landscape in this field. Consensus was reached in 70% of the statements (35/50). In addition, areas of warranted research were identified to guide future prospective clinical trials.
Oral Midodrine Administration During the First 24 Hours of Sepsis to Reduce the Need of Vasoactive Agents: Placebo-Controlled Feasibility Clinical Trial
Lal, Amos , Trivedi, Vrinda, Rizvi, Mahrukh, Amsbaugh, Amy, Myers, Melissa, Gajic, Ognjen, Myers, Melissa K, Lal, Amos , Saleh, Khaled Musa Mohammad , Kashyap, Rahul , Gajic, Ognjen

Mayo Clinic

Critical Care Explorations | May 9, 2021 | Volume: 3 | Issue: 5 | Pages: e0382

10.1097/cce.0000000000000382 | PMID 33977276 Get It

Objectives: Our preliminary data and observational studies suggested an increasing “off label” use of oral midodrine as a vasopressor sparing agent in various groups of critically ill patients, including those with sepsis. We designed this clinical trial to evaluate the feasibility of use of midodrine hydrochloride in early sepsis to reduce the duration for IV vasopressors and decrease ICU and hospital length of stay. Design: Pilot, two-center, placebo-controlled, double blinded randomized clinical trial. Setting: Medical ICUs at Mayo Clinic Rochester and Cleveland Clinic Abu Dhabi were the study sites. Patients and Methods: Adult patients (≥ 18 yr old) were included within 24 hours of meeting the Sepsis-3 definition if the mean arterial pressure remained less than 70 mm Hg despite receiving timely antibiotics and initial IV fluid bolus of 30 cc/kg. Intervention: Three doses of 10 mg midodrine versus placebo were administered. Measurements and Main Results: Total 32 patients were randomized into midodrine (n = 17) and placebo groups (n = 15). There were no major differences in baseline variables between the groups except for higher baseline creatinine in the midodrine group (2.0 ± 0.9 mg/dL) versus placebo group (1.4 ± 0.6 mg /dL), p = 0.03. The median duration of IV vasopressor requirement was 14.5 ± 8.1 hours in midodrine group versus 18.8 ± 7.1 hours in the placebo group, p value equals to 0.19. Patients in the midodrine group needed 729 ± 963 norepinephrine equivalent compared with 983 ± 1,569 norepinephrine equivalent in the placebo group, p value equals to 0.59. ICU length of stay was 2.29 days (interquartile range, 1.65–3.9 d) in the midodrine group, compared with 2.45 days (interquartile range, 1.6–3.2 d) in the placebo group, p value equals to 0.36. No serious adverse events were observed in either group. Conclusions: Phase II clinical trial powered for clinical outcomes (duration of vasopressor use, need for central venous catheter, and ICU and hospital length of stay) is justified.
Primary Cutaneous Enteric Duplication Cyst: A Novel Entity
Mastin, Murphy R., Swanson, Leah A., Smyrk, Thomas C., Wieland, Carilyn N., Guo, Ruifeng, Guo, Ruifeng , Swanson, Leah A. , Guo, Ruifeng , Mastin, Murphy R., Smyrk, Thomas C., Wieland, Carilyn N., Guo, Ruifeng

Mayo Clinic

The American Journal of Dermatopathology | May 9, 2021 | Volume: 43 | Issue: 12 | Pages: e245-e247

10.1097/dad.0000000000001960 | PMID 33958514 Get It

Abstract: Enteric duplication cysts (EDCs) are rare congenital malformations consisting of double-walled cystic or tubular structures lined by gastrointestinal type epithelium. EDCs share a common muscular wall and blood supply with the adjacent duplicated bowel with very rare exceptions. The majority of EDCs are intraabdominal with cases less commonly intrathoracic or thoracoabdominal. To the best of our knowledge, we present the first reported case of primary cutaneous EDC to occur outside the abdominal and thoracic cavities. A 17-year-old male without a significant medical or surgical history underwent excision of a cystic nodule on the left hip. On histopathology, a dermal to subcuticular cyst exhibited an epithelial lining with 2 distinct components including cuboidal to columnar mucinous cells (CK7+, CK20−, and CDX2−) and complex glandular colonic-type mucosa (CK7−, CK20+, and CDX2+). A thick muscular wall resembling muscularis mucosa and muscularis propria surrounded the cyst. Findings supported a primary cutaneous enteric duplication cyst of uncertain developmental etiology. The novel nature of this entity could represent a diagnostic challenge.
Response to Gualtieri et al.
Katzka, David A. , Ravi, Karthik , Dayyeh, Barham K. Abu

Mayo Clinic

American Journal of Gastroenterology | May 9, 2021 | Volume: 116 | Issue: 8 | Pages: 1755-1756

10.14309/ajg.0000000000001291 | PMID 34587129 Get It

American Medical Society for Sports Medicine Sports Ultrasound Curriculum for Sports Medicine Fellowships
Hall, Mederic M. , Bernhardt, David T., Hoffman, Douglas F. , Hrubes, Melody, Rao, Ashwin L., Ray, Jeremiah W. , Smith, Jay , Waterbrook, Anna L., Finnoff, Jonathan T. , Mautner, Kenneth

Mayo Clinic

Clinical Journal of Sport Medicine | May 9, 2021 | Volume: 31 | Issue: 4 | Pages: e176-e187

10.1097/jsm.0000000000000944 | PMID 33958521 Get It

Abstract: Sports ultrasound is commonly used by sports medicine physicians to enhance diagnostic and procedural accuracy. This expert consensus statement serves as an update to the 2015 American Medical Society for Sports Medicine recommended sports ultrasound curriculum for sports medicine fellowships. Although written in the context of the American sports medicine fellowship training model, we present a stepwise progression in both diagnostic and interventional sports ultrasound that may be applicable to the broader sports medicine community. The curriculum is divided into 12 units with each unit including didactic instructional sessions, practical hands-on instruction, independent scanning practice sessions, and mentored clinical experience. To assist with prioritization of learning, we have organized relevant pathology and procedures as essential, desirable, and optional. The expanded content can serve as an outline for continuing education postfellowship or for any physician to further advance their sports ultrasound knowledge and skill. We also provide updated scanning protocols, sample milestones, and a sample objective structured clinical examination (OSCE) to aid fellowships with implementation of the curriculum and ongoing assessment of fellow progress.
Complement testing in the clinical laboratory
Braun, Karin M P, Moyer, Ann M. , Jeffrey, David H., Frazer‐Abel, Ashley , Willrich, Maria Alice V.

Mayo Clinic

Critical Reviews in Clinical Laboratory Sciences | May 9, 2021 | Volume: 58 | Issue: 7 | Pages: 447-478

10.1080/10408363.2021.1907297 | PMID 33962553 Get It

Single-center comparison of gel microcolumn and solid-phase methods for antibody screening
Schmidt, A M, Bendix, Brenda J., Jacob, E, Bryant, S., Schmidt, A.M., Jacob, E.K., Stubbs, Jason R.

Mayo Clinic

Immunohematology | May 9, 2021 | Volume: 29 | Issue: 3 | Pages: 101-104

10.21307/immunohematology-2019-131 Get It

Abstract Our facility changed antibody screening methods from a gel microcolumn–based test (ID-Micro Typing System Gel Test; Ortho Clinical Diagnostics, Inc., Raritan, NJ) to an automated solid-phase test (Galileo/Capture-R Ready-Screen [I and II], Immucor, Inc., Norcross, GA). To determine whether detection rates for commonly encountered clinically significant red blood cell antibodies differed as a consequence of this change, preimplementation and postimplementation antibody identification records were retrospectively reviewed. A statistically significant difference in the percentage of positive screening tests during the gel microcolumn testing period (73,903 total screens, 1.56% confirmed positive) versus the solid-phase screening period (80,242 total screens, 1.81% confirmed positive; p < 0.0002) was observed. The number of antibodies to K identified was significantly lower with solid phase than with gel (27% decrease; p = 0.004). It is unknown whether there is a statistical difference in delayed or hemolytic transfusion reaction rates as this was not evaluated. Immunohematology 2013;29:101–04.
Immune response against Clostridioides difficile and translation to therapy
Sehgal, Kanika , Khanna, Sahil

Mayo Clinic

Therapeutic Advances in Gastroenterology | May 9, 2021 | Volume: 14 | Issue: No issue available | Pages: No page available

10.1177/17562848211014817 | PMID 33995585 Get It

The pathogenesis of Clostridioides difficile infection (CDI) has largely been attributed to the action of two major toxins – A and B. An enhanced systemic humoral immune response against these toxins has been shown to be protective against recurrent CDI. Over the years, fully human monoclonal antibodies against both of these toxins have been developed in an attempt to counter the increasing incidence of recurrent CDI. Clinical trials conducted to evaluate the efficacy of anti-toxin A monoclonal antibody, actoxumab, and anti-toxin B monoclonal antibody, bezlotoxumab, demonstrated that bezlotoxumab substantially lowered the rate of recurrent infection, while actoxumab did not. A significant therapeutic benefit was appreciated in patients with at least one high-risk factor for recurrence, including, age ⩾65 years, immunocompromised state, prior CDI and severe CDI. In light of toxins A and B being immunogenic, vaccine trials are underway with the aim to prevent primary infection.
A retrospective evaluation of highly active antiretroviral therapy simplification in patients with end-stage renal disease receiving hemodialysis
Otto, Ashley , Fulco, Patricia Pecora , Pecora Fulco, Patricia , Otto, Ashley O

Mayo Clinic

International Journal of STD & AIDS | May 9, 2021 | Volume: 32 | Issue: 10 | Pages: 963-967

10.1177/09564624211011902 | PMID 33969749 Get It

Antiretroviral (ARV) therapy in people living with HIV (PLWH) and end-stage renal disease (ESRD) on hemodialysis (HD) is complicated, requiring renally adjusted nucleoside reverse transcriptase inhibitors (NRTIs) and daily administration of non-renally eliminated agents. Recent data in PLWH with ESRD on HD demonstrate maintenance of viral suppression (82% with viral loads (VLs) <50 copies/mL) and favorable safety/tolerability profiles after ARV simplification with a fixed dose combination single tablet [elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide (E/C/F/TAF)]. Extrapolation of these data to all F/TAF formulations would allow ARV simplification to most PLWH with ESRD receiving HD. The objective of this retrospective study was to identify if ARV-experienced PLWH with ESRD on HD receiving renally adjusted NRTIs may be simplified to once daily ARV formulations without adverse effects while maintaining viral suppression. This single-center retrospective analysis assessed virologic control (3–12 months) and ARV tolerability post-regimen simplification (primarily NRTI once-daily dose adjustment) in PLWH with ESRD on thrice weekly HD receiving human immunodeficiency virus (HIV) care in an ambulatory clinic. Seventeen PLWH with ESRD on HD were included after documented ARV simplification. At 12 months, 12 patients (71%) remained undetectable (HIV VL <50 copies/mL) with two additional maintaining viral suppression (<200 copies/mL). One patient remained undetectable at month eight but became non-adherent with viral rebound. Two patients did not complete the 6- and 12-month evaluation after documented nonadherence ( N = 1) and an adverse effect (pruritus) ( N = 1). At 12 months, virologic suppression and tolerability resulted after a simplified ARV regimen including once daily F/TAF was initiated in PLWH with ESRD on thrice weekly HD with a reduction in pill burden.
Case Report: Opsoclonus-Myoclonus Syndrome Associated With Contactin-Associated Protein-Like 2 and Acetylcholine Receptor Autoantibodies in the Setting of Non-Small Cell Lung Carcinoma
Rosenow, Christian S. , Dawit, Sara, Farrugia, Luca, Henry, Katharine , Sharma, Akanksha , Porter, Alyx B. , Grill, Marie , Farrugia, Luca P, Henry Ma, Katharine A, Grill, Marie F, McKeon, Andrew

Mayo Clinic

The Neurohospitalist | May 9, 2021 | Volume: 12 | Issue: 1 | Pages: 100-104

10.1177/19418744211012899 | PMID 34950395 Get It

Opsoclonus myoclonus syndrome (OMS) is a rare immune-mediated paraneoplastic or para/-post-infectious syndrome characterized by “dancing” eye movements, myoclonus, and ataxia. Neuropsychiatric symptoms have also been reported. Without treatment, OMS may progress to further neurological impairment and even death. Autoimmune attack of CNS structures in OMS is most commonly mediated by anti-Ri (also known as ANNA2) IgG antibodies, with additional findings implicating antibodies targeting various neurotransmitter receptors. Prompt immunotherapy and neoplasm treatment may result in improvement. We report a novel association of Contactin-Associated Protein-Like 2 (Caspr2) antibodies occurring in association with paraneoplastic OMS. While breast cancer and small cell lung cancer (SCLC) are more commonly associated with OMS among adults, we characterize a novel association between Caspr2 antibody in a patient with mixed non-small cell and small cell lung carcinoma.